Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution;Anticorps monoclonaux dans le traitement de la polyarthrite rhumatoïde : vers une révolution thérapeutique

Comptes Rendus - Biologies

Volumn 329, Issue 4, 2006, Pages 228-240

  Sany, Jacques ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

Anti B lymphocytes monoclonal antibodies; Anti IL6 monoclonal antibodies; Anti TNF monoclonal antibodies; Monoclonal antibodies; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; ATLIZUMAB; B LYMPHOCYTE ANTIBODY; BCG VACCINE; CD20 ANTIBODY; CORTICOSTEROID; CYTOKINE; ETANERCEPT; HLA ANTIBODY; HLA ANTIGEN CLASS 2; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; POLYCLONAL ANTIBODY; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB; SALAZOSULFAPYRIDINE; T LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBODY; DISEASE TREATMENT; PATHOLOGY;

ARTICLE; ASPERGILLOSIS; AUTOIMMUNITY; B LYMPHOCYTE; BIOLOGICAL THERAPY; BRONCHOSPASM; CANDIDIASIS; DEMYELINATING DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG TARGETING; FEVER; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LISTERIOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OPPORTUNISTIC INFECTION; PANCYTOPENIA; PRESCRIPTION; REMISSION; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; T LYMPHOCYTE; TUBERCULOSIS; URTICARIA; VASCULAR DISEASE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645843911     PISSN: 16310691     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crvi.2005.12.008     Document Type: Article

References (58)

1. Sany J. Polyarthrite rhumatoïde de l'adulte. Conception actuelle (2003), John Libbey Eurotext, Paris
2. Feldmann M., Bremman F.M., and Maini R. Cytokines in autoimmune disorders. Int. Rev. Immunol. 17 (1998) 217-228
3. Breedveld F.C. Monoclonal antibodies to CD4. Rheumatic Disease Clinical North America (1998), W.B. Saunders, Philadelphie, PA, États-Unis 567-578
4. Sany J. Traitement de la polyarthrite rhumatoïde par des anticorps monoclonaux. Méd. Thér. 7 (2001) 420-425
5. Choy E.H.S., Kingsley G.H., and Panayi G.S. Monoclonal antibody therapy in rheumatoid arthritis. Br. J. Rheumatol. 37 (1998) 484-490
6. Choy E.H.S., Connolly D.J., Rapson N., Jeal S., Brown J.C.C., and Kingsley G.H. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology 39 (2000) 1139-1146
7. Sany J., Clot J., Bonneau M., and Andary M. Immunomodulating effect of human placenta-eluted gamma globulins in rheumatoid arthritis. Arthritis Rheum. 25 (1982) 17-24
8. Kavanaugh A.F., Davis L.S., Jain R.I., Nichols L.A., Norris S.H., and Lipsky P.E. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. 23 (1996) 1338-1344
9. Zhang Z., and Bridges L. Pathogenesis of rheumatoid arthritis, Role of B lymphocytes. Rheumatic Disease Clinics of North America (2001), W.B. Saunders, Philadelphie, PA, États-Unis 335-354
10. Oligino T.J., and Dalrymple S.A. Targeting B cells for the treatment of rheumatoid arthritis. Arthritis Res. Ther. 5 Suppl. 4 (2003) S7-S11
11. Matsumoto I., Maccioni M., Lee Dm., Maurice M., Simmons B., Brenner M., Matis D., and Benoist C. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat. Immunol. 4 (2002) 360-365
12. Edwards J.C.W., and Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40 (2001) 205-211
13. Leandro M.J., Edwards J.C., and Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 61 (2002) 883-888
14. De Vita S., Zaja F., Sacco S., De Candia A., Fanin R., and Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46 (2002) 2029-2033
15. Edwards J.C.W., Leandro M.J., and Cambridge G. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2004), W.B. Saunders, Philadelphie, PA, États-Unis 393-404
16. Edwards J.C.W., Szczepansici L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., Stevens R.M., and Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (2004) 2572-2581
17. Hainsworth J.D. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res. Ther. 5 Suppl. 4 (2003) S12-S16
18. Emery P., Filipowicz-Sosnowska A., Szczepanski L., Racwicz A., Schechtman J., and Fleischmann R.M. Primary analysis of a double blind, placebo-controlled, dose ranging trial of rituximab, an anti-CD20 monoclonal antibody in patients with rheumatoid arthritis receving methotrexate (DANCER trial). Ann. Rheum. Dis. 64 (Suppl. III) (2005) 58
19. Sany J. Conception actuelle du traitement de la polyarthrite rhumatoïde : vers une révolution thérapeutique ?. Bull. Acad. Nat. Méd. (Paris) 187 (2003) 957-976
20. Lipsky P.E., Van Der Heijde D.M., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1594-1602
21. St Clair E.W., Van Der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., Keystone E., Shiff M., Kalden J.R., Wang B., De Woody K., Weiss R., and Baker D. Combination of infliximab and methotrexate therapy for early r heumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
22. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., St Clair E.W., Keeman G.F., Van Der Heijde D.M., Marsters P.A., and Lipsky P.E. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50 (2004) 1051-1065
23. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoth L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 (2003) 35-45
24. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbira C.A., and Compagnone D. Adalimumab a fully human anti-tumor necrosis factor α monoclonal antibody and concomitant standard anti-rheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30 (2003) 2563-2571
25. Klareskog L., Van Der Heidje D., De Jager J.P., Gough A., Kalden J., Malaise M., Mola E.M., Pavelka K., Sany J., Settas L., Wajdula J., Pedersen R., Fatenejad S., and Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
26. Michaud K., and Wolfe F. Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Ann. Rheum. Dis. 64 Suppl. III (2005) 87 (résumé)
27. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannebaum H., Hua Y., Teoh L.S., Fischkoff S.A., and Chartash E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50 (2004) 1400-1411
28. Smolen J.S., Van Der Heidje D., and Emery P. Infliximab inhibits radiographic joint damage in patients with early rheumatoid arthritis regard less of clinical response after 54-week treatment. Ann. Rheum. Dis. 63 Suppl. I (2004) 260
29. Smolen J.S., Han C., Bala M., Maini R.N., Kalden J.R., Van Der Heidje D., Breedveld F.C., Furst D.E., Lipsky P.E., and the ATTRACT Study group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 52 (2005) 1020-1030
30. Quinn M.A., Conaghan P.G., O'Connor P.J., Karim Z., Greenstein A., Brown A., Brown C., Fraser A., Jarret S., and Emery P. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52 (2005) 27-35
31. Taylor P.C., Steuer A., Gruber J., Cosgrove D.O., Blomley M.J., Marsters P.A., Wagner C.L., Clinton M.C., and Maini Rn. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 50 (2004) 1107-1116
32. Buch M.H., Seto Y., Bingham S.J., Bejarano V., Bryer D., White J., and Emery P. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum. 52 (2005) 42-48
33. Mugnier B., Balandraud N., Darque A., Roudier C., Roudier J., and Reviron D. Polymorphism at position-308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 48 (2003) 1849-1852
34. Martinez A., Salido M., Bonilla G., Pascual-Salcedo D., Fernandez-Arquero M., De Miguel S., Balsa A., De La Concha Eg., and Fernandez-Gutierrez B. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum. 50 (2004) 1077-1082
35. Catrina A.I., Trollmo G., Af Klint E., Engstrom M., Klareskog L., and Ulfgren A.K. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum. 52 (2005) 61-72
36. Ehrenstein M.R., Evans J., Mathews C., Choudry F., and Mauri C. Regulatory T cells in rheumatoid arthritis before and after anti-TNF therapy. Ann. Rheum. Dis. 64 Suppl. 111 (2005) 39
37. Beenhouwer D., Wallis R., Broder M., and Furst D.E. Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections. J. Rheumatol. 31 (2004) 1888-1892
38. Sany J., Kaiser M.J., Jorgensen C., Zaltni S., and Trape G. Study of the tolerance of Infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64 11 (2005) 1647-1649
39. Wasserman M.J., Weber J.A., Guthrie J.A., Bykerk V.P., Lee P., and Keystone E.C. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J. Rheumatol. 31 (2004) 1912-1917
40. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindal E.A., Fleischmann R.M., and Bulpitt M.D. Etanercept therapy in rheumatoid arthritis. Ann. Int. Med. 130 (1999) 478-486
41. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.A., Keystone E.C., Wasko M.C., Moreland L.W., Weaver A.L., Markenson J., Cannon G.W., Spencer-Green G., and Finck B.K. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
42. Askling J., Fored C.M., Brandt L., Baecklund E., Bertisson L., Coster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Rantapaa-Dahlqvist S., Saxne T., Romanus V., Klareskog L., and Feltelius N. Risk case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52 (2005) 1986-1992
43. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., Carreno L., Figueroa M., and BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52 (2005) 1766-1772
44. Sibilia J. Anti-TNF et risque de néoplasie « solide ». Lettre du Rhumatologue 311 Suppl. (2005) 8-10
45. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18 572 patients. Arthritis Rheum. 50 (2004) 1740-1751
46. Symmons D.P., and Silman A.J. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum. 50 (2004) 1703-1706
47. De Rycke L., Baeten D., Kruithof E., Van Den Bosch F., Veys E.M., and De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 52 (2005) 2192-2201
48. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., and Braun M.M. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J. Rheumatol. 31 (2004) 1955-1958
49. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., and Stratigosa A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum. 52 (2005) 2513-2518
50. Choy E.H.S. Clinical experience with inhibition of interleukin-6. Rheum. Dis. Clin. North Am. (2004), W.B. Saunders, Philadelphie, PA, États-Unis 405-415
51. Takagi N., Mihara M., Moriya Y., Nishimoto N., Yoshizaki K., Kishimoto T., Takeda Y., and Ohsugi Y. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41 (1998) 2117-2121
52. Wendling D., Racadot E., and Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J. Rheumatol. 20 (1993) 259-262
53. Choy E.H.S., Isenberg D.A., Garrood T., Farrow S., Ioannou I., Bird H., Cheung N., Williams B., Hazleman B., Price R., Yoshizaki K., Nishimoto N., Kishimoto T., and Panayi G.S. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46 (2002) 3143-3150
54. Nishimoto N., Yoshizaki K., Miyasaka N., Yamamoto K., Takeuchi T., and Hashimoto F. A multicenter, randomized, double blind placebo controlled trial of humanized anti-interleukin 6 (IL6) receptor monoclonal antibody (MRA) in rheumatoid arthritis. Arthritis Rheum. 46 Suppl. (2002) S559
55. Maini R.N., and CHARISMA study Group. A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl. 64 (2003)
56. Iwamoto M., Nara H., Hirata D., Minota S., Nishimoto N., and Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 46 (2002) 3388-3389
57. De Benedetti F., and Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?. Arthritis Rheum. 52 (2005) 687-693
58. Yokota S., Miyamae T., Imagawa T., Iwata N., Katakura S., Mori M., Woo P., Nishimoto N., Yoshizaki K., and Kishimoto T. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52 (2005) 818-825